Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Different phenotypes of severe flares in patients with systemic lupus erythematosus: results of a clustering analysis in a monocentric cohort.

Frontiers in immunology·2025
Same author

Literature review and authors' consensus recommendations for the medical management of perianal fistulae in dogs.

Veterinary dermatology·2025
Same author

A blinded randomised split-body clinical trial evaluating the effect of fluorescent light energy on antimicrobial management of canine interdigital furunculosis.

Veterinary dermatology·2025
Same author

Posture and vision: How different distances of viewing target affect postural stability and plantar pressure parameters in healthy population.

Heliyon·2024
Same author

Efficacy and innocuity of lotilaner in the treatment of otodectic mange in ferrets.

Veterinary parasitology·2024
Same author

Clinical results in patients affected by moderate-severe knee osteoarthritis and treated with micro-fragmented adipose tissue: the therapeutic effects on symptomatology.

Musculoskeletal surgery·2024

Related Experiment Video

Updated: Jul 19, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Assessing remission in systemic lupus erythematosus.

M Mosca1, S Bombardieri

  • 1Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy. marta.mosca@int.med.unipi.it

Clinical and Experimental Rheumatology
|November 7, 2006
PubMed
Summary

Indices assess systemic lupus erythematosus (SLE) activity, damage, and QoL in research but not daily care. Establishing clear remission criteria beyond the SLE Disease Activity Index (SLEDAI) requires consensus on key factors.

Related Experiment Videos

Last Updated: Jul 19, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Area of Science:

  • Rheumatology
  • Clinical Immunology
  • Patient-Reported Outcomes

Background:

  • Multiple indices developed over decades to assess disease burden in systemic lupus erythematosus (SLE).
  • These tools are standard in clinical trials and research but underutilized in routine patient care.
  • Existing indices define disease flares and treatment response but lack clear remission criteria, with exceptions like the SLE Disease Activity Index (SLEDAI).

Purpose of the Study:

  • To highlight the gap in established remission criteria for SLE indices.
  • To emphasize the need for consensus on factors defining SLE remission.
  • To discuss the components required for objective remission definition in SLE.

Main Methods:

  • Review of existing indices for assessing SLE activity, damage, and quality of life (QoL).
  • Analysis of the current application of these indices in clinical research versus clinical practice.
  • Identification of challenges and requirements for establishing disease remission criteria.

Main Results:

  • Indices are validated and used in SLE research and trials, but not standard clinical practice.
  • Definitions for flares and treatment response exist, but consensus on remission criteria is lacking for most indices.
  • Objective remission definition requires agreement on the importance of systemic activity, organ-specific damage, QoL, and laboratory findings.

Conclusions:

  • Clear, objective criteria for SLE remission are needed for consistent patient management.
  • Defining SLE remission necessitates a multi-faceted approach considering disease activity, damage, QoL, and specific organ involvement.
  • Further research and consensus are required to establish robust remission criteria applicable across different SLE indices.